Biologic Therapeutic Drugs: Technologies and Global Markets
July 06, 2011
Wellesley, Mass. – In a recent release, BIOLOGIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (BIO079A) from BCC Research (www.bccresearch.com), the global market value of biologics was $149 billion in 2010. That value is projected to be $239 billion in 2015, after increasing at a five-year compound annual growth rate (CAGR) of 9.9%.
The global market for biologics can be broken down by product type into three segments – therapeutic proteins, monoclonal antibodies, and vaccines.
The segment made up of therapeutic proteins was valued at $72 billion in 2010, and in 2015 should be worth $107 billion, yielding a CAGR of 8.2%.
The segment made up of monoclonal antibodies was worth $48 billion in 2010, and should reach a value of $86 billion in 2015, a CAGR of 12.4%.
The segment made up of vaccines was valued at $29 billion in 2010, and in 2015 should be worth $46 billion, growing at a CAGR of 9.7%.
Biopharmaceuticals are often referred to as biologics, and they have important implications for the future of medicine and industry advancement. Market growth has been spurred recently by the need for a more extensive pipeline by drug companies, attractive targets against challenging diseases, a push by companies to pursue biosimilars, and enabling manufacturing technologies that reduce the cost to produce profitable products.
This report investigates one of the most important market drivers: specific product reviews of those programs expected to dominate the biopharmaceutical marketplace in the coming years. Additionally, the report addresses important topics such as the dynamics of the changing marketplace, emerging players and technologies, strategies for accessing emerging markets, and resource allocation in specific disease segments and geographies.
The intended audience of the report is mainly existing companies and emerging players in the biotechnology sector, but also includes business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, consultants, and anyone interested in the cardiovascular market, its products, its industry participants, and its future.
Biologic Therapeutic Drugs: Technologies and Global Markets( BIO079A )
Publish Date: Jan 2011
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
Reports from Cell Biology
Recent News
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum